Find us on Facebook

FDA Panel decides asthma drugs - Serevent and Oxis - aren’t worth the risk

FDA Panel decides asthma drugs - Serevent and Oxis - aren’t worth the risk

An FDA Panel said Thursday that the risks of death and serious injury associated with two popular brands of asthma inhalers are greater than the benefits of the drugs. However, in what is sure to be a controversial opinion, the panel said that Advair (Symbicort) should continue to be used to treat asthma.

The FDA has previously said that Serevent, Foradil (sold as Oxis in NZ), and similar drugs are linked to an increased risk of asthma-related side effects, particularly in children and the elderly. The side effects have resulted in injuries including asthma-related death, hospitalization, and asthma-related intubations, where a tube must be placed in patients’ noses or mouths to help them breathe.

The agency found an additional 2.8 asthma events per 1,000 patients treated with a LABA compared with patients not receiving the drugs. Note: Long-acting beta agonists (LABAS) are sold in NZ as Serevent, Oxis, and in combination with inhaled corticosteroid asthma drugs as Symbicort and Seretide.

http://www.attorneyatlaw.com/2008/12/fda-panel-serevent-foradil-aren%E2%80%99t-worth-risk-but-backs-advair/

Posted: Thu 11 Dec 2008

Back

View News index »

Helping people with breathing disorders since 2001

20 Arthur Street, Freemans Bay, Auckland 1011, New Zealand  |  Phone +64 9 360 6291  |  Email info@buteykobreathing.nz

Download our leaflets [PDFs]:  Do you suffer from asthma or allergies? »    Do you snore or suffer from sleep apnoea? »

BIBH logo
Registered Practitioner / Practitioner Trainer

PRIVACY POLICY
All cartoons courtesy of Chris Slane, Qantas Media Awards Cartoonist of the Year 2010  © slane.co.nz

Site design © e-compass.nz 2015